Option Care Health (OPCH) to Post Quarterly Earnings on Wednesday

Option Care Health (NASDAQ:OPCH) is expected to be issuing its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to post earnings of $0.42 per share and revenue of $1.4181 billion for the quarter. Option Care Health has set its FY 2026 guidance at 1.820-1.920 EPS. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:30 AM ET.

Option Care Health (NASDAQ:OPCH) last issued its earnings results on Thursday, April 30th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.03. Option Care Health had a net margin of 3.64% and a return on equity of 18.17%. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.39 billion. During the same quarter in the prior year, the business posted $0.40 EPS. The company’s revenue for the quarter was up 1.3% on a year-over-year basis. On average, analysts expect Option Care Health to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Option Care Health Stock Performance

Shares of NASDAQ OPCH opened at $21.66 on Monday. The company has a quick ratio of 1.07, a current ratio of 1.64 and a debt-to-equity ratio of 0.85. The stock’s 50 day moving average price is $21.32 and its two-hundred day moving average price is $27.09. Option Care Health has a 52-week low of $18.01 and a 52-week high of $36.80. The stock has a market capitalization of $3.40 billion, a P/E ratio of 16.79, a PEG ratio of 1.20 and a beta of 0.65.

Analyst Upgrades and Downgrades

OPCH has been the subject of several recent research reports. Morgan Stanley set a $28.00 target price on shares of Option Care Health in a research note on Wednesday, May 6th. Truist Financial set a $30.00 price target on Option Care Health in a report on Friday, May 1st. Weiss Ratings cut Option Care Health from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday. TD Cowen lowered their price target on shares of Option Care Health from $37.00 to $23.00 and set a “hold” rating for the company in a research report on Friday, May 1st. Finally, Zacks Research raised shares of Option Care Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Eight analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $30.08.

Insider Transactions at Option Care Health

In related news, Director Timothy P. Sullivan bought 24,154 shares of Option Care Health stock in a transaction dated Thursday, May 7th. The stock was acquired at an average cost of $20.69 per share, with a total value of $499,746.26. Following the completion of the acquisition, the director directly owned 73,383 shares in the company, valued at approximately $1,518,294.27. This trade represents a 49.06% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO John Charles Rademacher bought 12,500 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was purchased at an average price of $21.18 per share, with a total value of $264,750.00. Following the completion of the acquisition, the chief executive officer owned 695,152 shares of the company’s stock, valued at approximately $14,723,319.36. This trade represents a 1.83% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 73,264 shares of company stock valued at $1,548,316 in the last quarter. Insiders own 1.70% of the company’s stock.

Institutional Trading of Option Care Health

Several institutional investors have recently made changes to their positions in OPCH. UMB Bank n.a. grew its stake in shares of Option Care Health by 23.5% in the 4th quarter. UMB Bank n.a. now owns 1,715 shares of the company’s stock valued at $55,000 after buying an additional 326 shares in the last quarter. Wealthspire Advisors LLC lifted its stake in shares of Option Care Health by 6.2% in the fourth quarter. Wealthspire Advisors LLC now owns 11,172 shares of the company’s stock valued at $356,000 after buying an additional 648 shares during the period. Mariner LLC raised its stake in shares of Option Care Health by 7.1% in the fourth quarter. Mariner LLC now owns 10,060 shares of the company’s stock valued at $321,000 after purchasing an additional 663 shares in the last quarter. Parkside Financial Bank & Trust lifted its holdings in shares of Option Care Health by 9.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 8,718 shares of the company’s stock worth $278,000 after acquiring an additional 728 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its position in Option Care Health by 84.9% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 1,771 shares of the company’s stock worth $49,000 after purchasing an additional 813 shares in the last quarter. 98.05% of the stock is currently owned by institutional investors and hedge funds.

About Option Care Health

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.